NASDAQ
26.25USD
+0.37 (+1.43%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.9B
P/E
—
EPS
—
Beta
1.06
52W range
10.78-27.09
Day range
25.25–26.34
Open
26.20
Prev close
25.88
Volume
2M
Avg volume
2.1M
Dividend
0.00
IPO
2020-09-17
https://www.globenewswire.com/news-release/2026/07/22/3331062/0/en/Dyne-Therapeutics-Announces-Pricing-of-Upsized-375-Million-Public-Offering-of-Common-Stock.html · 7/22/2026+0.20
https://seekingalpha.com/article/4923532-dyne-therapeutics-a-buy-with-caveats-on-dmd-progress · 7/20/2026+1.00
https://www.fool.com/coverage/better-buy/2026/07/04/dyne-therapeutics-vs-recursion-pharmaceuticals-which-development-stage-pharma-stock-is-a-better-buy-in-2026/ · 7/4/2026+0.30
https://www.globenewswire.com/news-release/2026/02/22/3242282/0/en/Dyne-Therapeutics-Announces-Upcoming-Presentations-Across-Neuromuscular-Pipeline-at-2026-MDA-Clinical-Scientific-Conference.html · 2/22/2026+0.80
https://seekingalpha.com/article/4859980-dyne-therapeutics-inc-dyn-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript · 1/15/2026+0.10
https://seekingalpha.com/article/4851192-dyne-therapeutics-inc-dyn-discusses-positive-topline-results-from-deliver-registrational · 12/8/2025+0.90
https://www.globenewswire.com/news-release/2025/12/07/3201141/0/en/Dyne-Therapeutics-to-Host-Investor-Conference-Call-and-Webcast-to-Review-Topline-Results-from-Registrational-Expansion-Cohort-REC-of-DELIVER-Clinical-Trial-of-Z-Rostudirsen-DYNE-25.html · 12/7/2025+0.10
https://www.fool.com/coverage/filings/2025/12/03/dyne-therapeutics-stock-down-30-in-a-year-so-why-did-one-investor-add-nearly-1-million-shares/ · 12/3/2025+0.40
https://www.defenseworld.net/2025/11/15/arcadia-investment-management-corp-mi-raises-stake-in-dyne-therapeutics-inc-dyn.html · 11/15/2025+0.30
https://seekingalpha.com/article/4833603-wall-street-breakfast-podcast-novartis-puts-12b-on-the-table · 10/27/2025+0.80
https://www.defenseworld.net/2025/10/26/dyne-therapeutics-inc-nasdaqdyn-given-average-rating-of-moderate-buy-by-brokerages.html · 10/26/2025+0.60
https://www.globenewswire.com/news-release/2025/10/06/3162171/0/en/Dyne-Therapeutics-Announces-Additional-One-Year-Clinical-Data-Demonstrating-Functional-Improvement-from-Phase-1-2-ACHIEVE-Trial-of-Zeleciment-Basivarsen-DYNE-101-for-Myotonic-Dystr.html · 10/6/2025+1.00
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
